ESR1 and breast carcinoma: Therefore, the protein level and activation of Pak4 may potentially affect the effectiveness of anti-estrogen therapies; this is consistent with previous reports of Pak1 signaling-dependent activation of ER-S305 leading to enhanced S118 phosphorylation, and development of tamoxifen resistance in breast cancer [11].